Hansa Biopharma to participate in LSX Congress USA in Boston

Lund, Sweden, September 21, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Fredrik Röök, VP Business Development at Hansa Biopharma, will participate in the panel discussion “Breaking into New Markets: Strategies for Global Biopharma Expansion” at LSX Congress USA in Boston at 11:00 a.m. EST on Wednesday, September 23, 2026.

If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event: Panel discussion at LSX Congress USA

Title: Breaking into New Markets: Strategies for Global Biopharma Expansion

Date, Time and Place: Wednesday 23 September, 11:00 EST, Boston

Moderator: Pankaj Oza, Managing Partner, Blue Matter Consulting

Speakers:

Fredrik Röök, VP Business Development, Hansa Biopharma
Mike Patten, Chief Strategy Officer, Harbour BioMed
Abhijit Bhatia, Chief Operating Officer, Rakuten Medical
Suguna Rachakonda, SVP, Strategy & BD, Micro CRISPR

--- ENDS ---

Contacts for more information:

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.